MedTrace Logo

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

NCT07803991 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-09-04

No results posted yet for this study

Summary

To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

DRUG

SYH2069 Injection

0.6ml , 1.2ml , administered subcutaneously (SC)，Administer the drug according to the clinical trial protocol

DRUG

SYH2069 Injection Placebo

0.6ml , 1.2ml , SC，Administer the drug according to the clinical trial protocol

Sponsors & Collaborators

  • CSPC Ouyi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07803991 on ClinicalTrials.gov